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Leprosy is an infectious, neurodegenerative disease of humans caused by Mycobacterium leprae. Despite
effective control programs, the incidence of leprosy remains stubbornly high, suggesting that transmission may
be more common than expected. The rationale of this work was to use bioinformatics and comparative
genomics to identify potentially antigenic proteins for diagnostic purposes. This approach defined three classes
of proteins: those restricted to M. leprae (class I), those present in M. leprae with orthologues in other
organisms besides mycobacteria (class II), and exported or surface-exposed proteins (class III). Twelve genes
(two class I, four class II, and six class III proteins) were cloned in Escherichia coli, and their protein products
were purified. Six of these proteins were detected in cell extracts of M. leprae by immunoblotting. The
immunogenicity of each recombinant protein was then investigated in leprosy patients by measuring the
reactivity of circulating antibody and gamma interferon (IFN-) responses in T-cell restimulation assays.
Several class II and class III proteins were recognized by circulating antibodies. Importantly, most class II
proteins elicited IFN- responses that were significantly stronger than those produced by previously identified
antigens. Among them, two class II proteins, ML0308 and ML2498, showed marked humoral and cellular
immunogenicity, therefore providing promising candidates for the diagnosis of both tuberculoid and lepro-
matous forms of leprosy.
Mycobacterium leprae, the etiologic agent of leprosy, has
undergone a reductive evolutionary process through adapta-
tion to its intracellular parasitic lifestyle. Its genome contains
1,614 genes coding for proteins and 1,133 pseudogenes, the
largest number described to date for a bacterium (12). The
genes encoding all the biosynthetic pathways have been re-
tained, whereas those coding for many catabolic pathways and
the respiratory chains and several genes involved in DNA
replication, recombination, and repair are missing or seriously
impaired (12). Nevertheless, this minimal gene set is sufficient
for M. leprae to colonize macrophages and Schwann cells and
to cause serious damage to the human peripheral nervous
system (27).
Leprosy remains a public health problem in spite of the
global coverage of multidrug therapy (MDT) promoted by the
World Health Organization (WHO) and the dramatic de-
crease in prevalence. However, the number of new cases of
leprosy has remained obstinately constant in the last decade
(30). Leprosy develops after an estimated incubation period of
2 to 10 years and shows a complex spectrum of clinical forms
(23). Tuberculoid leprosy (TT) and lepromatous leprosy (LL)
are polar and stable forms of leprosy. TT patients are charac-
terized by strong local cell-mediated immunity and a bacterial
index (BI) of zero in the lesions. In contrast, LL patients
display M. leprae-specific systemic T-cell anergy, a high BI, and
a strong humoral response. Between the LL and TT poles,
three unstable interpolar forms of leprosy coexist, i.e., border-
line tuberculoid, borderline borderline, and borderline lepro-
matous forms (BT, BB, and BL, respectively) (23). They are
characterized by a gradual degradation of cell-mediated im-
munity in parallel with an increase in the BI and the humoral
response from the interpolar BT toward the interpolar BL
leprosy type. BT, BB, and BL leprosy patients may experience
a type I reaction, or reversal reaction, which is marked by an
amelioration of the cellular immune response that could lead
to nerve damage. Some BL leprosy patients develop a type 2
reaction, or erythema nodosum leprosum, a painful, immuno-
logically mediated inflammatory condition. Both the reversal
reaction and erythema nodosum leprosum can occur before,
during, and after MDT (5, 20).
In countries where leprosy is endemic, leprosy diagnosis is
mainly based on clinical symptoms and occasionally verified by
light microscopy. The availability of a diagnostic method has
long been desired to detect infection and the presence of
multiplying M. leprae before clinical signs become apparent.
The discovery and characterization of phenolic glycolipid 1
(PGL-1) provided hope for the development of a specific test
for leprosy, and much effort was devoted to detecting circulat-
ing antibodies as a test for infection (8, 9). Unfortunately,
anti-PGL-1 immunoglobulin M (IgM) antibodies are abundant
in LL patients and scarce or absent in TT patients. Addition-
ally, PGL-1 itself is an unusually stable molecule, often per-
sisting in patients who have completed MDT. Mitsuda intro-
duced an intradermal skin test, in which a cell-mediated immune
response to lepromin, a complex mixture of proteins derived
from extracts of heat-killed M. leprae, is assessed (20). Because
of the anergy that characterizes LL patients, these individuals
are lepromin negative, therefore reducing the utility of this
test. Nevertheless, tests based on protein or peptide antigens
* Corresponding author. Mailing address: Unite´ de Ge´ne´tique Mo-
le´culaire Bacte´rienne, Institut Pasteur, 28 rue du Docteur Roux, 75724
Paris Cedex 15, France. Phone: 33 (0)1 45 68 84 46. Fax: 33 (0)1 40 61
35 83. E-mail: stcole@pasteur.fr.
175
 o
n
 June 18, 2014 by YO
NSEI UNIV M
ED LIBRARY
http://iai.asm
.org/
D
ow
nloaded from
 
still offer great promise for identifying recently infected per-
sons or TT cases and other borderline patients, provided that
their cell-mediated immunity remains vigorous. A potentially
confounding factor, however, is previous immunization with
related cross-reacting antigens such as those present in Myco-
bacterium bovis BCG or environmental mycobacteria.
Two new approaches have been used to develop improved
skin test antigens. Firstly, armadillo-derived M. leprae cells
have been fractionated, and the proteins associated with the
membrane, cell wall, and cytoplasm have been purified and
immunologically characterized (21). This first generation of
antigens, which comprised the most abundant M. leprae pro-
teins (i.e., major membrane protein I [MMP-I], MMP-II, an-
tigen 85-B [Ag85B], elongation factor Tu [EF-Tu], and
GroES), encountered serious problems of cross-reactivity with
their counterparts in pathogenic as well as environmental my-
cobacteria (3, 10, 31). Peptide antigens representing poten-
tially M. leprae-specific epitopes were used to evaluate re-
sponses in leprosy patients and healthy individuals from areas
where leprosy is not endemic. Although initial findings were
promising, immunological responses to these peptides were of
poor specificity and sensitivity (13).
With the availability of the complete genome sequences of
M. leprae (12), the principal members of the M. tuberculosis com-
plex (11, 15), and four environmental mycobacteria, M. avium,
M. smegmatis, M. marinum, and the emerging pathogen M. ulcer-
ans, we are now ideally positioned to adopt a more rational route
to antigen discovery. Using genomics and bioinformatics, sets of
potential antigens can be defined that are restricted to M. leprae,
including secreted or surface-exposed proteins, and screened in
silico for potential T-cell epitopes. After validation, these new
antigens could serve as the basis of a diagnostic test capable of
revealing infection before clinical signs become apparent or of
detecting early stages of leprosy.
MATERIALS AND METHODS
Bioinformatic methods. Potential coding sequences were predicted and analyzed
as previously described, using Artemis for annotation (12, 24, 26). We conducted a
search for genes that fulfilled one of the following criteria: (i) present inM. leprae but
absent from all other genomes, (ii) present in M. leprae but absent from all other
mycobacterial genomes, and (iii) coding for secreted and/or exported and surface-
exposed proteins with restricted distribution. To this end, the genome of M. leprae
was compared with the genomes of M. tuberculosis (http://genolist.pasteur.fr
/TubercuList/), M. bovis (http://genolist.pasteur.fr/BoviList/), M. avium, M. smegmatis
(both available athttp://www.tigr.org/tdb/mdb/mdbinprogress.html), M. marinum
(http://www.sanger.ac.uk/Projects/M_marinum), and M. ulcerans (http://www
.pasteur.fr/recherche/unites/Lgmb/mycogenomics.html).
Each protein sequence of M. leprae served as a query sequence against the
proteomic data in public databases, using FASTA and BLASTP. The resulting
proteins were classified into three classes according to the above conditions and
are described in Table 1.
Cloning, overexpression, and purification of recombinant M. leprae proteins.
A group of 12 coding sequences coding for two proteins from class I, four
proteins from class II, and six proteins from class III were selected and cloned
using the Gateway in vitro recombination method (Invitrogen) (2). Each target
gene was amplified by PCR from genomic clones selected from Lorist6- and
pYUB18-based cosmid libraries (Table 2). PCR products were first subcloned into
the shuttle vector pDONR201, and the resulting products (entry clones) were mixed
with the expression vector pDEST17 (destination vector). The reaction products
were transformed into Escherichia coli DH5 cells. After screening, DNAs of se-
lected recombinant clones were prepared with QIAfilter (QIAGEN Inc., Valencia,
CA) and sequenced on an ABI 3700 DNA analyzer. The E. coli strain BL21(DE3)
was used for protein expression (Table 2). Cells were grown in 1 liter of 2YT
medium supplemented with ampicillin (100 g/ml) at 20°C or at 37°C. The cells
were then harvested by centrifugation, and cell pellets were washed once with
protein extraction buffer containing 100 mM sodium phosphate buffer, 150 mM
NaCl, pH 7, before centrifugation and resuspension in 50 ml of protein extrac-
tion buffer supplemented with a cocktail of protease inhibitors (Complete;
TABLE 1. Potential antigenic targets selected in silico
Class Accessionno.
Functional
categorya Function Mr
I ML0008 8 Unknown 13,722.5
ML0126 8 Unknown 30,831.8
ML0678 8 Unknown 19,767.5
ML0757 8 Unknown 24,909.2
ML0957 8 Unknown 13,939.6
ML1057 8 Unknown 12,207.9
ML1420 8 Unknown 13,138.9
ML1603 8 Unknown 9,376.0
ML1829 8 Unknown 13,334.3
ML1915 8 Unknown 12,433.0
ML1979 8 Unknown 14,233.5
ML2244 8 Unknown 12,552.1
ML2249 8 Unknown 11,200.5
ML2252 8 Unknown 8,720.8
ML2264 8 Unknown 22,683.5
ML2283 8 Unknown 11,758.5
ML2567 8 Unknown 17,051.2
II ML0308 10 Conserved hypothetical
protein
25,899.1
ML0333 10 Conserved hypothetical
protein
26,453.1
ML0336 3 ABC transporter
ATP-binding protein
30,185.6
ML0394 7 Methyltransferase 19,170.1
ML0397 3 Transporter 63,963.7
ML0398 3 D-Ribose binding protein 36,939.9
ML0447 10 Conserved hypothetical
protein
17,104.5
ML0458 7 Oxidoreductase 32,874.6
ML0578 7 Phosphoenolpyruvate
carboxylase
102,515
ML1419 9 Regulatory protein 60,968.8
ML1553 2 Prolyl tRNA synthetase 53,584.9
ML2177 7 Uridine phosphorylase 35,081.0
ML2341 9 Transcriptional regulatory
protein
78,379.4
ML2346 10 Conserved hypothetical
protein
33,938.9
ML2498 1 Enoyl-CoA hydratase 23,119.4
ML2649 7 Oligosaccharide deacetylase 29,553.7
III ML0376 3 Membrane protein 36,916.8
ML0410 6 PE3 (PE family protein) 10,951.4
ML0466 3 Secreted protein 32,914.4
ML0568 3 Secreted protein 18,361.6
ML0842 7 Cysteine desulfurase 44,537.5
ML1053 6 PE5 (PE family) 10,117.0
ML1055 3 EsxK1 (ESAT-6 family) 11,298.6
ML1056 3 EsxL1 (ESAT-6 family) 10,260.2
ML1182 6 PPE9 (PPE family) 43,119.6
ML1795 0 HSP 18 16,706.9
ML1828 6 PPE12 (PPE family) 59,192.3
ML2088 7 Putative cytochrome P450 47,154.3
ML2242 10 Conserved hypothetical
protein
25,730.2
ML2531 3 EsxH (ESAT-6 family) 10,392.6
ML2532 3 EsxG (ESAT-6 family) 10,191.3
ML2534 6 PE10 (PE family) 10,243.6
ML2667 3 Membrane transport
protein
65,080.5
a Functional categories: 0, virulence, detoxification, adaptation; 1, lipid metabo-
lism; 2, information pathways; 3, cell wall and cell processes; 6, PE/PPE; 7, inter-
mediate metabolism and respiration; 8, unknown; 9, regulatory proteins; 10, con-
served hypothetical.
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Roche Diagnostics GmbH, Mannheim, Germany). The cells were lysed by son-
ication (Branson Sonifier 250). Lysates were centrifuged at 18,000  g (Eppen-
dorf centrifuge 5810R) for 30 min at 4°C, and the pellets were resuspended in 30
ml of 6 M guanidine hydrochloride, 100 mM sodium phosphate, 300 mM NaCl,
pH 8. The whole suspension, previously clarified by centrifugation, was loaded
into a 2-ml Ni-nitrilotriacetic acid-agarose superflow column using a fast-perfor-
mance liquid chromatography device at a flow rate of 0.5 ml/min. Protein elution
was monitored at 280 nm. The column was washed successively with buffer
containing 8 M urea, 100 mM sodium phosphate, and 300 mM NaCl set at
different pHs (8.0, 6.4, and 5.9) at a flow rate of 1 ml/min to remove nonspecifi-
cally bound proteins. All proteins were eluted with 8 M urea, 100 mM sodium
phosphate, 300 mM NaCl, pH 4.15. The eluted proteins (30 to 60 ml) were
dialyzed against 100 mM ammonium carbonate buffer, pH 7. Insoluble proteins
were recovered by centrifugation (18,000  g, 4°C, 30 min), and solubilized
proteins were concentrated by lyophilization. Protein concentrations were de-
termined by the Bradford method (Bio-Rad, Munich, Germany). The Limulus
amebocyte lysate test (BioWhittaker, Verviers, Belgium) was used to ensure that
samples contained no detectable lipopolysaccharide. The following recombinant
proteins of M. leprae were used as controls (Yonsei University, Korea): the
35-kDa MMP-I, the 22-kDa MMP-II, the 34.8-kDa Ag85B, the 43.6-kDa EF-Tu,
and GroES, the 10-kDa heat shock protein.
Immunodetection of recombinant proteins in cellular extracts of M. leprae.
Polyclonal antibodies for immunodetection were generated in rabbits by intra-
dermally injecting 250 g of the recombinant proteins emulsified in 1 ml of
phosphate-buffered saline (PBS)–incomplete Freund’s adjuvant (1:1). Immuni-
zation was repeated four times. The sera were titrated by an indirect enzyme-
linked immunosorbent assay (ELISA), with the recombinant proteins (10 g/ml)
as the coating layer. Lyophilized cellular extracts of M. leprae, kindly provided by
John Spencer (Colorado State University) (22), were resuspended in 1 M urea
and 5 Laemmli sample buffer in order to obtain a final protein concentration
of 2 mg/ml. Thirty micrograms of cytosolic, membrane, and cell wall fractions was
electrophoresed in a 13% or a 10 to 20% sodium dodecyl sulfate (SDS)-poly-
acrylamide gel. The proteins were electrotransferred onto Hybond-C membranes
(Amersham Biosciences, Arlington Heights, IL), which were immediately
blocked overnight with 0.5% bovine serum albumin (BSA) in Tris-buffered saline
(TBS; 50 mM Tris-HCl, 150 mM NaCl, pH 7.5) at 4°C. The membranes were
washed three times with TBS, soaked at room temperature for 1 h in 0.5%
BSA–TBS, pH 7.5, and then incubated either with immune serum or with
preimmune serum as a control. The membranes were washed three times with
TBS and were incubated for 1 h with horseradish peroxidase-conjugated anti-
rabbit IgG (Amersham Biosciences). Chemiluminescence detection using an
ECL kit (Amersham Biosciences) was visualized with an LAS 3000 image
reader (Fujifilm). Independent experiments were performed at least three times.
Study population. The population used to screen for protein immunogenicity,
as measured by gamma interferon (IFN-) release, was composed of 25 former
leprosy patients. They were diagnosed clinically, bacteriologically, and histolog-
ically from 1986 to 2003 at the Korean Institute of Leprosy Research, Euiwang
City, Republic of Korea. Six BT, two BB, eight BL, and nine LL patients
comprised this group. Seven were BI positive at the time of sampling, and 18
were BI negative; 12 patients were positive for anti-PGL-1 antibodies, while 13
were negative (9). At the time of the experiment, 11 patients were being treated
with MDT, 5 were being treated with dapsone, and 9 had received no treatment.
All subjects gave their informed consent prior to venipuncture. The appropriate
local ethics committees granted approval for this study.
Whole blood assay. IFN- measurements in whole blood restimulation assays
were performed as described previously (17, 28, 29). Briefly, 5 ml of blood was
taken by venipuncture from each patient and immediately mixed with heparin at
a concentration of 20 U/ml. The blood was diluted 10-fold with sterile RPMI
1640 tissue culture medium containing 100 U/ml penicillin, 100 mg/ml strepto-
mycin, and 2 mM L-glutamine. Proteins (10 g/ml), concanavalin A, phytohe-
magglutinin (5 to 10 g/ml), M. leprae soluble antigens (MLSA), or medium
alone was added to the wells of 96-well round-bottomed tissue culture plates in
a volume of 20 l, to which 180 l of diluted blood was added within 2 to 4 hours
of blood collection. Tests were carried out in triplicate. After 5 days of incubation
in a 37°C incubator in the presence of 5% CO2, supernatants were frozen at
20°C until analysis. The supernatants were subsequently tested for IFN- in an
ELISA using BD OptEIA set human IFN- (BD Biosciences, San Diego, Calif.).
Cytokine production was calculated for triplicate wells after the subtraction of
nonspecific cytokine production in nonstimulated cultures.
Human serum samples. Sera from 42 anonymous leprosy patients were se-
lected from the leprosy serum collection of the Department of Microbiology,
Yonsei University, and were manipulated according to standard procedures. The
patients were classified clinically as 3 BT, 1 BB, 24 BL, and 14 LL cases and were
all BI positive (range, 1.8 to 5.0), and their sera contained antibodies to PGL-1
in all but 5 cases. All patients were being treated with MDT at the time of
sampling. Sera from 21 healthy, BCG-vaccinated Korean controls were used for
control purposes, and these contained no antibodies to PGL-1. The internal
review boards at Yonsei University College of Medicine approved the use of
these serum samples for our purposes. Sera were screened for the presence of
antibodies to the recombinant M. leprae proteins ML0308, ML1553, ML2177,
ML2498, ML0410, ML1053, ML1055, and ML1056 as described previously (25).
Briefly, 100 l of recombinant antigen (10 g/ml in 0.1 M carbonate-bicarbonate
buffer, pH 9.6) was used to coat the wells of 96-well flat-bottomed ELISA plates
(Nunc) at 4°C overnight. The plates were washed with PBS, 0.05% Tween 80, pH
7.5 (PBS/T), four times, and the wells were blocked with PBS–1% BSA in PBS/T,
pH 7.5. The serum samples were diluted 1:200 in 5% goat serum (Invitrogen,
Carlsbad, CA) in PBS/T, pH 7.5, and 100 l of this dilution was added to the
wells. Following 2 h of incubation at room temperature, the plates were washed
four times as described above, and 100 l of horseradish peroxidase-conjugated
goat anti-human IgG (Calbiochem, San Diego, California) was added at a dilu-
tion of 1:10,000 in 5% goat serum in PBS/T, pH 7.5. After 2 h of incubation at
room temperature and washing, 100 l of o-phenylenediamine (Sigma, St. Louis,
Missouri) was added. After 15 min, the reaction was stopped with 100 l of 0.5
M H2SO4, and the absorbance at 490 nm was read. Sera were tested in duplicate.
To normalize the background, we used the mean absorbance of the control wells
without antigens.
TABLE 2. Genomic clones, expression vectors, protein expression of M. leprae recombinant proteins, and antiserum titers
Accession no. Class a Functional category(function)b
Genomic clone
(cosmid) Mr Mr with His tag
Protein expression conditions
(strain/yield [mg liter1]/
temp [°C])
Antiserum titer c
ML0757 I 8 (unknown) MLCY024 24,909 27,542 BL21/3/20–37 1/3,200
ML1057 I 8 (unknown) B1912 12,207 14,840 BL21/2/20–37 1/2,500
ML0308 II 10 (conserved hypothetical) MLCY174 25,899 28,532 BL21-GC/5/20 1/3,200
ML1553 II 2 (prolyl tRNA synthetase) B0596 53,584 56,267 BL21/3/37–20 1/5,000
ML2177 II 7 (uridine phosphorylase) L0611 35,081 37,714 BL21/3/20–37 1/2,500
ML2498 II 1 (enoyl-CoA hydratase) MLCY609 23,119 25,752 BL21/4/37 1/5,000
ML0410 III 6 (PE family) B1620 10,951 13,584 BL21/6/20–37 1/5,000
ML1053 III 6 (PE family) B1912 10,117 12,750 BL21/4/37 1/10,000
ML1055 III 3 (ESAT-6 family) MLCY258 11,298 13,931 BL21/5/37 1/10,000
ML1056 III 3 (ESAT-6 family) B1912 10,260 12,893 BL21/7/37 1/2,500
ML1182 III 6 (PPE family) B1701 43,119 45,752 BL21-GC/3/20 1/1,600
ML2534 III 6 (PE family) MLCY693 10,243 12,876 BL21-pLys/3/20 1/5,000
a I, restricted to M. leprae; II, has orthologues in other organisms besides mycobacteria; III, surface-exposed or exported proteins of limited distribution.
b Functional categories: 1, lipid metabolism; 2, information pathways; 3, cell wall and cell processes; 6, PE/PPE; 7, intermediate metabolism and respiration;
8, unknown; 10, conserved hypothetical.
c Antiserum titers from rabbits immunized intradermally with 250 g recombinant protein.
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RESULTS
Definition of new protein antigens in silico. Comparative
genomics was used to identify potential protein antigens that
could ultimately serve as the basis for an immunodiagnostic
test for leprosy. To optimize the potential specificity of our
candidates, we selected proteins with limited distribution in
other bacterial genomes. At the start of this project, 136 genes
were known to be restricted to the M. leprae genome (class I)
(12). However, since some of them were likely to correspond to
pseudogenes or gene fragments, a reanalysis of class I genes
was performed with more stringent criteria, such as the codon
usage, GC content, and positional base preference routines
contained in Artemis (24). This selection reduced our class I
candidates to a set of 17 proteins that were likely to be strictly
M. leprae specific. Class II genes have orthologues or paral-
ogues in species other than mycobacteria, and several of them
are predicted to encode enzymes. Of the 29 class II genes, 16
were retained for further analysis, including those for several
conserved hypothetical proteins, uridine phosphorylase, and
an enoyl-coenzyme A (CoA) hydratase. Class III contains 17
proteins that are likely to be exported or surface exposed, with
several of them being members of the PE and PPE (derived
from the motifs Pro-Glu [PE] and Pro-Pro-Glu [PPE], respec-
tively) or ESAT-6 (6-kDa early secreted antigenic target) pro-
tein family, first described for M. tuberculosis (11) but now
known to be present in many mycobacteria. Six class III pro-
teins with limited distribution are absent from M. tuberculosis
but present in Mycobacterium avium subsp. paratuberculosis
(ML0376, ML0466, ML0842, ML1795, ML2242, and ML2667). The
complete list of the selected class I, II, and III candidate
antigens is presented in Table 1.
Cloning, overexpression, and purification of recombinant M.
leprae proteins. Candidate genes were subcloned into pDEST17
vectors, thereby introducing a His-tag motif, MSYYHHHHH
HLESTSLYKKAGS, at the N terminus to simplify protein
purification. All of the recombinant proteins were insoluble,
regardless of the growth conditions and bacterial host strains.
Expression yields could be improved by modifying E. coli
growth conditions in some instances (Table 2). The expression
of ML1182 was only possible in strain BL21 CodonPlus (DE-
3)-RP (Stratagene). The ML1553, ML2177, and ML2498
genes, which encode the prolyl-tRNA synthetase, uridine phos-
phorylase, and enoyl-CoA hydratase enzymes, respectively,
were cloned into pBAD vectors to achieve tighter regulation of
protein expression, but nevertheless, the expression products
remained insoluble. All recombinant proteins were purified by
affinity chromatography under denaturing conditions.
Figure 1 shows the electrophoretic profiles of the resulting
purified recombinant proteins. Some candidates, such as
ML1053, a PE protein, formed multimeric bands resistant to
SDS, dithiothreitol, and boiling. However, contamination with
other proteins was excluded, as electrospray ionization mass
FIG. 1. Electrophoretic profiles of recombinant proteins. Electro-
phoresis was done on 13% (A) or 10 to 20% gradient (B and C) SDS-
polyacrylamide gels. FIG. 2. Subcellular localization of native proteins in armadillo-de-
rived M. leprae. (A) ML0757; (B) ML0308; (C) ML1553; (D) ML2498;
(E) ML0410. Fractions ofM. lepraewere separated by electrophoresis and
blotted onto Hybond-C membranes, and immunodetection was per-
formed with rabbit antisera. rProt, purified recombinant protein; CYT,
cytoplasmic fraction; MB, membrane fraction; CW, cell wall fraction.
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spectrometry analysis confirmed the homogeneity of the prep-
aration and the expected molecular weight (data not shown).
ML1553, ML1182, and ML2498 showed a tendency to de-
grade. The homogeneity of the protein samples was verified by
Western blot analysis using anti-His-tag polyclonal antibodies
(data not shown).
Immunolocalization of native M. leprae proteins. Before un-
dertaking immunological studies, we examined whether our
candidate antigens were immunogenic in animal models.
When rabbits were immunized with the recombinant proteins,
immune sera with potent reactivities were generated, as mea-
sured by antibody titers in an ELISA (Table 2).
These polyclonal antibodies were then used to probe West-
ern blots of cell extracts of armadillo-derived M. leprae to
determine if our candidate antigens are expressed in the bacilli
and to investigate their subcellular localization. Figure 2 shows
that the class I protein ML0757 (Mr, 24,909) was detected in
both the cytosolic and cell wall fractions. Conversely, neither
the recombinant ML0757 protein nor the M. leprae fractions
reacted with preimmune serum (Fig. 2A). The class II hypo-
thetical protein ML0308 was located in all three subcellular
fractions, with the expected molecular weight (Mr, 25,899)
(Fig. 2B), and appeared to be more abundant in the membrane
fraction of M. leprae. The putative prolyl tRNA synthetase
(ML1553; Mr, 53,584) was detected mainly in the membrane
fraction, although a weak band with a similar mass was also
observed in the cytosolic fraction (Fig. 2C). ML2498, a putative
enoyl-CoA hydratase (Mr, 23,119), was located in the membrane
fraction (Fig. 2D). A class III protein member, ML0410 (Mr,
10,951), belonging to the PE family was detected in the mem-
brane fraction (Fig. 2E), while another PE protein, ML1053, was
detected in both the cytosolic and membrane fractions (data not
shown). Control blots for ML0308, ML1553, ML2498, ML1053,
and ML0410 with preimmune sera were all negative (data not
shown). ML1057 (class I), ML2177 (class II), ML1182, ML2534,
ML1055, and ML1056 (all class III) could not be detected by
immunoblotting with immune sera.
Circulating antibodies against M. leprae proteins. Since all
12 candidate antigens were immunogenic in animal models
and since 6 of 12 proteins were detectable in cell extracts of
M. leprae, we then examined if immune responses to any of
these antigens were measurable in infected humans. We first
investigated whether our candidates generated antibody re-
sponses in leprosy patients by testing the reactivities of 42
serum samples to the recombinant proteins in an ELISA. In
control experiments, sera from 21 healthy Korean individuals
were tested for reactivity. As shown in Fig. 3, MLSA was
strongly recognized by patient sera, with a mean optical den-
sity (standard deviation) of 0.83  0.6, whereas the mean
value for healthy controls was only 0.13  0.3. The ML0308,
ML1553, ML2177, ML2498, ML0410, ML1053, ML1055, and
ML1056 proteins were also recognized by circulating antibod-
ies, although to a lesser extent than MLSA. The other proteins
did not elicit any signals (data not shown). Among the reactive
FIG. 3. Antibody responses against candidate M. leprae antigens. Sera from 42 individuals with leprosy and 21 healthy controls were tested in
duplicate, and the mean absorbance for control wells without antigen was subtracted from that for sample wells before analysis. Open symbols
correspond to sera from leprosy patients (L), and solid symbols correspond to sera from healthy controls (H). Horizontal bars indicate the resulting
mean values for each M. leprae recombinant protein. OD, optical density.
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antigens, the class II protein ML0308 showed the best signal,
with a mean optical density of 0.21  0.16 for patient sera
compared to a value of 0.02  0.06 for control sera, followed
by the class III proteins ML0410 and ML1053 (mean values of
0.16  0.20 and 0.27  0.19, respectively, for patient sera, and
0.08  0.08 and 0.02  0.012, respectively, for healthy control
sera). However, the ML1055, ML1553, and ML2177 proteins
also reacted to a similar extent with sera from healthy controls,
indicating that they may share cross-reacting epitopes with
proteins from other organisms.
IFN- responses in leprosy patients and healthy controls.
We then examined if a group of Korean leprosy patients who
had been treated and cured showed IFN- responses to our
candidate antigens. For this purpose, T-cell restimulation as-
says were performed on whole blood samples. Potent and
comparable IFN- production levels were generated in re-
sponse to stimulation with phytohemagglutinin and concanava-
lin A in all patients (data not shown) and in response to
stimulation with MLSA in all but 4 of 25 patients (Fig. 4).
In the first experiment, the IFN- responses of lymphocytes
to the candidate proteins ML0308, ML1053, ML1055, and
ML1056 were compared to the responses to M. leprae antigens
with established immunogenicity, such as MMP-I, MMP-II,
antigen 85-B, EF-Tu, and GroES, in eight former leprosy pa-
tients. Two sets of recombinant proteins, namely, ML1553,
ML2177, ML2498, and ML0410 and ML0757, ML1057, and
ML1182, were tested in two independent experiments, with
each including 10 former leprosy patients. Figure 4 shows that
of the 12 candidate antigens, proteins ML0757, ML1057 (both
class I), and ML1055 (class III) did not elicit significant IFN-
production in leprosy patients, whereas the other candidates
from class II and class III did, especially ML2177, ML2498,
and the PE proteins ML0410 and ML1053. In particular, these
last candidates showed stronger IFN- responses than the po-
FIG. 4. IFN- responses to candidate M. leprae antigens in former leprosy patients. Diluted whole blood samples from 25 former leprosy
patients were stimulated for 5 days in vitro, and their IFN- production was measured as mean values, in pg ml1, of triplicate wells after
subtraction of the nonspecific cytokine production level in unstimulated cultures. Horizontal bars indicate the resulting mean values for each
antigen.
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tent antigen Ag85B, illustrating their potential use for leprosy
diagnosis. We were unable to establish a clear correlation
between the IFN- response and the type of leprosy, although
cells from BT leprosy patients were slightly more productive,
possibly as a result of the patients having received MDT. In
control experiments performed with lymphocytes from healthy
individuals from France, much lower or insignificant levels of
IFN- were detected after incubation with each of the recom-
binant M. leprae proteins (data not shown).
DISCUSSION
Since the leprosy elimination program started in 1991, the
global prevalence of the disease has dropped dramatically
(90%). Some 112 of the 125 countries where leprosy is en-
demic have reached the WHO’s proposed goal, namely, a
prevalence of 	1 per 10,000 inhabitants. Nowadays, the num-
ber of new cases detected yearly, at 
500,000, is greater than
that predicted by WHO, despite the massive use of MDT, and
this may be a consequence of the relatively long incubation
period of the disease. Many factors concerning leprosy trans-
mission remain poorly understood. With the aim of developing
a specific immunological test for the diagnosis of leprosy be-
fore the clinical signs become apparent, we have applied com-
parative genomics and bioinformatics to define a set of 50
potential antigens. Some of these appear to be restricted to
M. leprae, while others have a wider distribution and include
proteins that are likely to be secreted or surface exposed.
Here we have produced and characterized the first 12 pro-
teins from our antigen discovery project and report the iden-
tification of 6 of them in subcellular compartments of M. leprae
by immunodetection. Our inability to detect the remaining six
proteins may indicate that they are of low abundance or are
unstable in extracts of armadillo-derived M. leprae, despite the
inclusion of protease inhibitors. Other workers have reported
similar discrepancies (21). Recently, a proteomic analysis of
soluble/cytosolic and membrane fractions of M. leprae led to
the identification of 147 protein spots, but none of these cor-
responded to proteins in this study (22). Our work thus en-
riches our knowledge of the M. leprae proteome. Class I pro-
teins are restricted to the leprosy bacillus, but their existence is
hypothetical since they show no sequence similarity to known
proteins. Furthermore, because of their small size, there is also
a risk that some of them may correspond to pseudogene prod-
ucts. Further in silico refinement using more stringent criteria
led us to focus on 16 of the 136 candidates (Table 1). Two class
I proteins, ML0757 and ML1057 (Table 2), were analyzed in
this work, and ML0757 was detected in cell extracts of the
bacillus, where it was found in the cell wall fraction. Both
ML0757 and ML1057 induced weak IFN- responses, thus
indicating that the proteins are present during infection. These
results confirmed the bioinformatic predictions and encourage
us to examine more class I proteins in future work.
Class II proteins, some of which have putative functions but no
known counterparts in mycobacteria, yielded the best results in
the immunological analysis. While most of the M. leprae genes
have orthologues in M. tuberculosis, some genes show stronger
similarity to their eukaryotic equivalents and are in all probability
the result of horizontal gene transfer events (7, 12, 14). Examples
of this may be found in the ML1553 gene, encoding a eukaryotic-
like prolyl tRNA synthetase, and the ML2177 gene, coding for a
uridine phosphorylase that resembles the mouse enzyme. In con-
trast, the ML2498 gene codes for an enoyl-CoA hydratase that is
typically prokaryotic, and the ML0308 gene encodes a conserved
hypothetical protein with orthologues in archaebacteria (http:
//genolist.pasteur.fr/Leproma/). All four of these proteins are an-
tigenic in humans and recognized by T cells and/or antibodies
(Fig. 3 and 4).
Class III proteins are likely to be secreted or present in the
cell envelope, and some of them belong to the PE, PPE, and
ESAT-6 protein families that are confined to mycobacteria (1,
4, 6, 11). Several members of these protein families from
M. tuberculosis are known to be immunodominant antigens
that are strongly recognized by T cells, a highly desirable prop-
erty for the development of an immunodiagnostic test. The
best studied of these is the ESAT-6 protein, a potent T-cell
antigen, which is used as part of a diagnostic test for tubercu-
losis in humans and cattle (18, 19, 32). Initial work by Otten-
hoff et al. (16) confirmed the immunodominance of the
M. leprae ESAT-6 orthologue, ML0049, but showed that prob-
lems of potential cross-reactivity arise in individuals likely to
have been infected or exposed to M. tuberculosis. The sequence
of the M. leprae orthologue of CFP-10 has 40% identity (60%
homology) at the protein level with M. tuberculosis CFP-10 and
may also be subject to cross-recognition. For this reason, we
have concentrated on other, more divergent members of the
ESAT-6 family of M. leprae, namely, ML1055 and ML1056,
together with one PPE protein (ML1182) and three PE pro-
teins (ML0410, ML1053, and ML2534). Nevertheless, the
ESAT-6 protein ML1055 (EsxK1), but not ML1056 (EsxL1),
appears to cross-react with sera from healthy individuals
(Fig. 3).
While the ESAT-6 family proteins stimulated low levels of
IFN- production by lymphocytes, the PE proteins ML0410
and ML1053 seemed to be far more immunogenic. These an-
tigens, together with the four from class II, represent promis-
ing candidates for further testing in order to appraise their true
diagnostic potential. One of the shortcomings of the present
antigen discovery program was the use of blood from MDT-
treated leprosy patients rather than from untreated patients,
who are more likely to be encountered in the field and for
whom a better diagnostic test is required. In the next phase of
this work, which will be limited to the best protein candidates,
both alone and in combination, we will perform more extensive
controls using whole blood assays of both healthy and diseased
individuals from areas where leprosy is endemic and will also
include subjects suffering from tuberculosis to determine pos-
sible cross-reactivity. Only in this way will we able to assess the
specificity and sensitivity of these antigens and to establish
their usefulness for developing a specific immunological test
for the early diagnosis of leprosy. Early detection will result in
the prompt initiation of multidrug therapy, thereby increasing
the possibility that both the prevalence and the incidence of
leprosy can be further reduced.
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